No quarterly revenue total was found in Protara Therapeutics, Inc.'s SEC filings.
Protara Therapeutics, Inc. (TARA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$15.7 million. As of Jun 30, 2026 it held $161.8 million in cash and investments and $2.7 million in total debt.
Revenue
—
Net income
$-21.67M
-44.8% vs year-ago quarter
Operating cash flow
$-15.39M
-25.6% vs year-ago quarter
Free cash flow
$-15.68M
-27.3% vs year-ago quarter
EPS
$-0.36
-2.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
59.10M
+53.2% vs year-ago quarter
Net cash
$159.10M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TARA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1359931
- Former names
- Protara Therapeutics, Inc. (until Aug 13, 2026); ArTara Therapeutics, Inc. (until Apr 23, 2020); PROTEON THERAPEUTICS INC (until Dec 31, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$23.3M | -$19.6M | -$19.1M | -$14.8M | -$16.6M |
| Net income | -$21.7M | -$17.8M | -$17.3M | -$13.3M | -$15.0M |
| Diluted EPS | -$0.36 | -$0.31 | -$0.38 | -$0.31 | -$0.35 |
| Operating cash flow | -$15.4M | -$21.3M | -$16.9M | -$12.5M | -$12.2M |
| Free cash flow | -$15.7M | — | -$17.0M | -$12.5M | -$12.3M |
| Total assets | $176.1M | $191.9M | $209.5M | $144.6M | $156.9M |
| Total liabilities | $14.8M | $10.7M | $13.1M | $12.3M | $12.5M |
| Stockholders' equity | $161.3M | $181.2M | $196.4M | $132.3M | $144.4M |
| Cash and investments | $161.8M | $177.4M | $197.9M | $133.6M | $145.6M |
| Total debt | $2.7M | $3.1M | $3.4M | $3.7M | $3.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 29, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2026 | Jun 12, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 809 Protara Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.